Abstract P2141: Effect Of Anakinra On Peak Oxygen Consumption In Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis

• Published in: Circulation research 2023-08, Vol.133 (Suppl_1)
• Main Authors: Jain, Manisha, Meenashi Sundaram, Dakshin, Mahfooz, Kamran, Gaddipati, Sai Pranathi, Ramnani, Subhav, Baig, Kaunain, Kaur, Gurmehak, Gudi, Thulasi Ram, Vasavada, Advait
• Format: Article
• Language: English
• ISSN: 0009-7330; 1524-4571
• DOI: 10.1161/res.133.suppl_1.P2141

Abstract only Background: Peak oxygen consumption(VO2) evaluates an individual's aerobic fitness level, and provides information on overall health and fitness. Prior studies on anakinra in heart failure have not evaluated VO2 specifically in the subgroup of heart failure with reduced ejection fraction(HFrEF). Our aim was to evaluate the effect of this drug in this population. Methods: We searched five databases: Embase, MEDLINE, Cochrane, Scopus, and PubMed, for RCTs evaluating the effects of Anakinra against a placebo in HFrEF. Meta-analysis was performed using RevMan 5.4 and a random-effects model was used for the analysis. Three RCTs were identified Results: The analysis of the Anakinra effect on VO2 in patients with HFrEF was determined using 3 RCTs. Most studied its effect after 2 weeks. Compared to placebo/standard treatment, anakinra was associated with a greater change in peak VO2 from baseline VO2. However, the difference between Anakinra and placebo in peak VO2 changes was not statistically significant (MD 0.07, 95% CI -0.41 to 0.56; I2 = 43%) with an overall test effect of Z = 0.29 at p = 0.77. The VE/VCO2 slope determined the effect of Anakinra on ventilatory efficiency in HF patients. Among the 3 RCTs that evaluated VE/VCO2 slope, no difference was depicted between the Anakinra treatment relative to placebo. Thus, the statistical difference was insignificant between the two groups (MD 0.70, 95% CI -0.06 to 1.46; I2 = 0%) at p = 0.07. Conclusion: Anakinra was ineffective in improving VO2 in HFrEF. Future prospective studies with longer duration of treatment and measuring performance monitoring outcomes are needed to understand the effect of this drug for such outcomes.